AccessibilityHelpAbout Us
Premier Biomedical logo

Premier Biomedical(OTC) BIEI

Market Cap$844.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-89%
1 Year-32%
1 Month-12%
$0.00
+0.00%
+0.00Today
Premier Biomedical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-25
Premier Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%USD 0.002026-09-18
1 month-12.28%USD 0.002026-08-26
3 month-44.44%USD 0.002026-06-26
Year to date+11.11%USD 0.002025-12-31
1 year-32.43%USD 0.002025-09-25
3 year-44.44%USD 0.002023-09-26
5 year-89.13%USD 0.002021-09-24
Since inception-100%USD 287.502012-08-08

Premier Biomedical Financials at a Glance

Market Cap

$844.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$58.30K

Net Income (TTM)

-$52.47K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$0.00

Volume

9,613,219

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

BIEI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Premier Biomedical

Premier Biomedical, Inc. is a research-based company focused on discovering and developing innovative medical products for the treatment of PTSD, cancer, and various other diseases. The company offers a range of pain management products and is actively developing new therapies, including hemp oil-based solutions and a sequential-dialysis technique for serious health conditions.

Products and Services
  • Hemp oil-based pain relief patches and topical products
  • Sequential-dialysis technique for cancer and other diseases
  • Feldetrex drug candidate for multiple sclerosis and traumatic brain injuries
Growth Outlook
  • Recent quarterly revenue of $58,300 indicates potential for growth
  • Development of innovative therapies may attract new partnerships
  • Focus on expanding product offerings in the healthcare sector
Financial Highlights
  • Trailing twelve months (TTM) revenue of $58,300 shows initial sales momentum
  • Gross profit margin of 56.6% reflects strong product demand
  • Operating income of $19,011 in Q2 2026 demonstrates operational efficiency
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Ivan Mendez

Website

www.premierbiomedical.com

Headquarters

Jackson Center, PA 16133, US

BIEI Financials

Key Financial Metrics (TTM)

Gross Margin

56.60%

Operating Margin

-90.00%

Net Income Margin

-90.00%

Return on Equity

2.02%

Return on Capital

N/A

Return on Assets

-110.47%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$844.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.69B

Volume

9.61M

Avg. Volume

15.36M

Financials (TTM)

Gross Profit

$33.00K

Operating Income

-$52.47K

EBITDA

-$52.47K

Operating Cash Flow

-$190.49K

Capital Expenditure

$0.00

Free Cash Flow

-$190.49K

Cash & ST Invst.

$791.00

Total Debt

$740.60K

Premier Biomedical Performance Analysis

Premier Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Premier Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Premier Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.00N/A
20232023-12-31USD -0.00N/A
20242024-12-31USD -0.00-50.0%
20252025-12-31USD -0.000.0%
Premier Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$58.30K

N/A

Gross Profit

$33.00K

N/A

Gross Margin

56.60%

N/A

Market Cap

$844.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$211.23K

N/A

Employees

4

N/A

Net Income

$19.01K

+211.8%

EBITDA

$19.01K

+211.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$791.00

+97.8%

Total Debt

$740.60K

+2.8%

Accounts Receivable

$43.58K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$740.60K

+2.8%

Return on Assets

-1.10%

N/A

Return on Invested Capital

2.04%

N/A

Free Cash Flow

-$19.50K

-764.6%

Operating Cash Flow

-$19.50K

-764.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ITNSItonis, Inc.
$0.00+0.00%
MSMYMC Endeavors, Inc.
$0.00+0.00%
DYNTDynatronics Corporation
$0.04+0.00%
VRTHFIndigenous Bloom Hemp Corp.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About BIEI

What is the current price of Premier Biomedical?

Premier Biomedical is trading at $0.00 per share.

What is the 52-week range for Premier Biomedical?

Over the past 52 weeks, Premier Biomedical has traded between $0.00 and $0.00.

How much debt does Premier Biomedical have?

As of the most recent reporting period, Premier Biomedical reported total debt of $740.60K.

How much cash does Premier Biomedical have on hand?

Premier Biomedical reported $791.00 in cash and cash equivalents in its most recent financial results.

What is Premier Biomedical’s dividend yield?

Premier Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services